Quirky China trend shows kids, pets hugging giant winter melons to stay cool at night
BEIJING: The scorching summer heat in China has sparked a trend where people hug a giant winter melon while sleeping to find relief from the sweltering temperatures.
The topic 'sleeping with a winter melon is cooler than using an air conditioner' has gone viral on mainland social media, with one Chinese platform alone garnering 4.4 million views.
Many individuals shared photos of themselves slumbering while clutching these large vegetables, which are comparable in size to a toddler, highlighting their remarkable cooling effects.
A resident of northern China's Tianjin municipality, known as Longma, claimed to be among the first to introduce this effective cooling method that ignited the trend.
She purchased a 14kg winter melon from the local market for her child, who complained that the summer heat was making it difficult for him to sleep at night.
Longma noted that she refrained from using air conditioning in the bedrooms to avoid catching a cold, and saw the 'ancient method' of hugging a winter melon as a viable alternative.
Each day, she would gently pat the vegetable to monitor its condition, stating that her winter melon remained in excellent shape after 26 days.
Many families have purchased these vegetables for their children and pets, with photos capturing them snugly clinging to the melons during their sleep. - Photo: RedNote
Another participant from eastern China's Anhui province admitted she felt foolish purchasing a 21kg winter melon at the market, but was pleasantly surprised to discover it was indeed effective.
She mentioned that by keeping the white wax on the melons, they can remain fresh longer.
Numerous people have bought these vegetables for their children and pets. Judging by how tightly they cling to the melons while asleep in the videos, it seems to provide significant benefits.
This method is also quite economical. One individual reported that her 14kg winter melon cost only 54 yuan (US$7.5).
Many have noted they could use the same melon for several days. However, one person cautioned against eating the melon, stating: 'The one people have slept with does not taste good.'
It is said that sleeping while hugging a winter melon is an ancient Chinese remedy for cooling down in the summer.
The vegetable contains over 95 per cent water, which aids in absorbing heat through skin contact.
Traditional Chinese medicine (TCM) also incorporates the vegetable's rind in prescriptions aimed at clearing heat from the body.
TCM expert Yang Zufu from the China Recovery Research Centre explained to People's Daily that this method can benefit those unable to use air conditioning, including the elderly, toddlers, and pregnant women.
However, individuals with weak spleens and stomachs are advised against pressing their bellies against the vegetable for extended periods, as it may exacerbate symptoms like stomach pain or diarrhoea.
Yang recommended that those with sensitivities wrap the melons in towels and position them at a slight distance to minimise side effects.
'Watermelon is also effective, but they're too delicious to resist,' one commenter remarked.
'It stops being funny when you try sleeping with one – it's really useful!' another noted.
A third chimed in: 'So that's why they named it winter melon – to bring some winter to the summer.' - South China Morning Post
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
7 hours ago
- The Star
Peer pressure and stress fuel drug use among youth, says Yeoh
CURIOSITY, stress and peer influence are among the main reasons why young Malaysian end up with substance abuse issues, says Hannah Yeoh ( pic ). The Youth and Sports Minister was citing the findings of a behavioural study conducted in selected high risk areas by the Malaysian Institute for Youth Research (Iyres) between September 2024 and February this year. 'The findings revealed that among the factors leading respondents to use drugs and illegal substances were curiosity (30.1%), stress (20.9%) and peer influence (18.9%),' she said in a written reply to Datuk Seri Ismail Abd Muttalib (PN-Maran). While there may have been a slight decrease in the overall number of drug addicts, she noted the number of youths involved with drugs had increased. 'Based on statistics from the National Anti-Drug Agency (AADK), the number of drug and substance abuse cases among youths, aged between 15 and 30 years, had increased over the past two years. 'In 2023, a total of 46,401 youths were identified as being involved. This number rose 19.3% to 55,369 individuals in 2024,' she said. Malay youth represented the largest group, accounting for 76% of the total in both years. 'The number increased from 35,280 individuals (2023) to 42,076 individuals (2024), marking a 19.3% increase,' she added. Indian youth recorded an increase of 1,014 individuals (34.5%), up from 2,937 in 2023 to 3,951 in 2024. 'Chinese youth showed an increase of 446 individuals (19.3%), from 2,312 in 2023 to 2,758 in 2024,' added Yeoh. Indigenous youth from Sabah and Sarawak recorded increases of 8.7% and 8.9%, respectively. Yeoh said that several measures have been implemented to curb the rise in substance abuse, including the launch of the Drug Free Youth Campaign on April 21 together with relevant stakeholders, police, AADK and Universiti Malaya Medical Centre. She also said the Central Agency for Application for Filming and Performance by Foreign Artistes had been urged to adopt improved guidelines to better protect youths against the dangers of substance abuse.
New Straits Times
15 hours ago
- New Straits Times
Gaza facing deadly hunger crisis, warns WHO
GENEVA: The World Health Organization's chief warned Wednesday of widespread starvation in Gaza, saying food deliveries into the war-ravaged Palestinian territory were "far below what is needed for the survival of the population." "A large proportion of the population of Gaza is starving. I don't know what you would call it other than mass starvation – and it's man-made," Tedros Adhanom Ghebreyesus told reporters. His statement added his voice to those of 111 aid organisations and rights groups, including MSF and Oxfam, who warned earlier Wednesday that "mass starvation" was spreading in Gaza. "Our colleagues and those we serve are wasting away," they said in a joint statement. Israel is facing mounting international pressure over the catastrophic humanitarian situation in Gaza, where more than two million people are facing severe shortages of food and other essentials after 21 months of conflict. Even after Israel began easing a more than two-month aid blockade in late May, Gaza's population is still suffering extreme scarcities. "The 2.1 million people trapped in the war zone that is Gaza are facing yet another killer on top of bombs and bullets: starvation," Tedros said. "We are now witnessing a deadly surge in malnutrition-related deaths," he added. Tedros highlighted that "rates of global acute malnutrition exceed 10 per cent, and over 20 per cent of pregnant and breastfeeding women that have been screened are malnourished, often severely." The UN health agency has documented 21 deaths in Gaza related to malnutrition of children under the age of five since the beginning of the year, but acknowledges that the true number is likely higher. The head of Gaza's largest hospital said Tuesday that 21 children had died due to malnutrition and starvation in the Palestinian territory over the previous three days alone. Tedros warned that "the hunger crisis is being accelerated by the collapse of aid pipelines and restrictions on access." The starvation is "man-made" and clearly caused by Israel's blockade on the territory, he said. The WHO chief highlighted how starving people were risking their lives to access aid. The UN rights office said Tuesday that Israeli forces have killed more than 1,000 Palestinians trying to get food aid in Gaza since the US- and Israel-backed Gaza Humanitarian Foundation started operations in late May. "Not only 1,026 were killed while trying to feed themselves or find food for their family. Thousands were also wounded," Tedros said. "We demand that there is full access, and we demand that there is a ceasefire," he said. "We demand that there is a political solution to this problem, a lasting solution."--AFP
Malaysian Reserve
16 hours ago
- Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /CNW/ — USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. 'I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event,' said Jared Kelly, CEO of Oncolytics. 'Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers.' The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of 'cold‑to‑hot' tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. 'The collection of data here show that pelareorep works how a cancer immunotherapy should work,' said Jared Kelly, CEO of Oncolytics. 'Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs.' Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications,' said Kelly. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy.' As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. 'I'm thrilled to join Oncolytics at such a pivotal moment in its evolution,' said Aromando. 'With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.' Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. 'The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care,' said Dan Passeri, CEO of Cue Biopharma. 'With this maturing data, we are further emboldened in our conviction that our Immuno-STAT® platform represents transformative potential for selectively modulating the patient's immune system.' Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. 'The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer,' said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. 'The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation.' Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile.' The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
